The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
It is the first autotaxin inhibitor to be investigated in cancer patients
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Subscribe To Our Newsletter & Stay Updated
